Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic predictors of GLP1 receptor agonist weight loss and side effects.

Nature - 1 May 2026

Su Qiaojuan Jane, Ashenhurst James R, Xu Wanwan, Tran Vinh, Ryanne Wu R, Weldon Catherine H, Shi Jingchunzi, Hicks Barry, Abul-Husn Noura S, Aslibekyan Stella, Holmes Michael V, Koelsch Bertram L, Auton Adam

Abstract excerpt

The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity. However, substantial inter-person variability exists in both weight loss efficacy and the incidence of side effects1. To investigate the genetic basis of this variability, here we conduct a genome-wide association study of self-reported...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Mutation, Missense

Share to Nausea

Share to Obesity

Share to Treatment Outcome

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 41951734
DOI: 10.1038/s41586-026-10330-z
PMCID: PMC13190316

Genes

GIPR
GLP1R

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic predictors of GLP1 receptor agonist weight loss and side effects.PMID 41951734Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

Pharmacogenomics of Anti-Obesity Drugs: A Bioinformatics ApproachSemantic proximity Read ↗

Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity Read ↗

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiencySemantic proximity Read ↗

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity Read ↗

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanksSemantic proximity Read ↗

GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.Semantic proximity Read ↗

Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.